Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
Alterations in the composition or function of the gut microbiota are associated with the etiology of human diseases. Drug-microbiota interactions can affect drug bioavailability, effectiveness, and toxicity through various routes. For instance, the direct effect of microbial enzymes on drugs can eit...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1189036/full |
| _version_ | 1797671551651282944 |
|---|---|
| author | Junyu Fan Junyu Fan Ting Jiang Ting Jiang Dongyi He Dongyi He Dongyi He |
| author_facet | Junyu Fan Junyu Fan Ting Jiang Ting Jiang Dongyi He Dongyi He Dongyi He |
| author_sort | Junyu Fan |
| collection | DOAJ |
| description | Alterations in the composition or function of the gut microbiota are associated with the etiology of human diseases. Drug-microbiota interactions can affect drug bioavailability, effectiveness, and toxicity through various routes. For instance, the direct effect of microbial enzymes on drugs can either boost or diminish their efficacy. Thus, considering its wide range of metabolic capabilities, the gut microbiota is a promising target for pharmacological modulation. Furthermore, drugs can alter the microbiota and the mechanisms by which they interact with their host. Individual variances in microbial profiles can also contribute to the different host responses to various drugs. However, the influence of interactions between the gut microbiota and drugs on treatment efficacy remains poorly elucidated. In this review, we will discuss the impact of microbiota dysbiosis in the pathogenesis of rheumatoid arthritis (RA), and we will attempt to elucidate the crosstalk between the gut microbiota and disease-modifying anti-rheumatic drugs (DMARDs), with an emphasis on how drug-microbiota interactions affect the treatment efficacy in RA. We speculate that improved knowledge of these critical interactions will facilitate the development of novel therapeutic options that use microbial markers for predicting or optimizing treatment outcomes. |
| first_indexed | 2024-03-11T21:17:12Z |
| format | Article |
| id | doaj.art-b2a76e7fe9ac460ba3c4926095900870 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-11T21:17:12Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-b2a76e7fe9ac460ba3c49260959008702023-09-28T16:59:37ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-09-011410.3389/fimmu.2023.11890361189036Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritisJunyu Fan0Junyu Fan1Ting Jiang2Ting Jiang3Dongyi He4Dongyi He5Dongyi He6Department of Rheumatology, Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, ChinaDepartment of Rheumatology, Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, ChinaDepartment of Rheumatology, Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, ChinaInstitute of Arthritis Research in Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, ChinaAlterations in the composition or function of the gut microbiota are associated with the etiology of human diseases. Drug-microbiota interactions can affect drug bioavailability, effectiveness, and toxicity through various routes. For instance, the direct effect of microbial enzymes on drugs can either boost or diminish their efficacy. Thus, considering its wide range of metabolic capabilities, the gut microbiota is a promising target for pharmacological modulation. Furthermore, drugs can alter the microbiota and the mechanisms by which they interact with their host. Individual variances in microbial profiles can also contribute to the different host responses to various drugs. However, the influence of interactions between the gut microbiota and drugs on treatment efficacy remains poorly elucidated. In this review, we will discuss the impact of microbiota dysbiosis in the pathogenesis of rheumatoid arthritis (RA), and we will attempt to elucidate the crosstalk between the gut microbiota and disease-modifying anti-rheumatic drugs (DMARDs), with an emphasis on how drug-microbiota interactions affect the treatment efficacy in RA. We speculate that improved knowledge of these critical interactions will facilitate the development of novel therapeutic options that use microbial markers for predicting or optimizing treatment outcomes.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1189036/fullgut microbiotadysbiosisrheumatoid arthritisimmune responseDMARDs |
| spellingShingle | Junyu Fan Junyu Fan Ting Jiang Ting Jiang Dongyi He Dongyi He Dongyi He Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis Frontiers in Immunology gut microbiota dysbiosis rheumatoid arthritis immune response DMARDs |
| title | Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis |
| title_full | Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis |
| title_fullStr | Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis |
| title_full_unstemmed | Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis |
| title_short | Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis |
| title_sort | advances in the implications of the gut microbiota on the treatment efficacy of disease modifying anti rheumatic drugs in rheumatoid arthritis |
| topic | gut microbiota dysbiosis rheumatoid arthritis immune response DMARDs |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1189036/full |
| work_keys_str_mv | AT junyufan advancesintheimplicationsofthegutmicrobiotaonthetreatmentefficacyofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritis AT junyufan advancesintheimplicationsofthegutmicrobiotaonthetreatmentefficacyofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritis AT tingjiang advancesintheimplicationsofthegutmicrobiotaonthetreatmentefficacyofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritis AT tingjiang advancesintheimplicationsofthegutmicrobiotaonthetreatmentefficacyofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritis AT dongyihe advancesintheimplicationsofthegutmicrobiotaonthetreatmentefficacyofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritis AT dongyihe advancesintheimplicationsofthegutmicrobiotaonthetreatmentefficacyofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritis AT dongyihe advancesintheimplicationsofthegutmicrobiotaonthetreatmentefficacyofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritis |